Skip to main content
. 2021 Jan 4;5(4):573–588. doi: 10.1002/hep4.1657

Fig. 4.

Fig. 4

Time course of PRO‐C3/C3M in the main (A) and OLE (B) studies. Both the main and OLE times are shown in (B). Res/Res patients were on resmetirom for both the main and OLE 36‐week studies, and Pbo/Res were on placebo during the main study and started on resmetirom on OLE day 1 for 36 weeks.